Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Breast-conserving surgery (BCS) is traditionally followed by radiotherapy to the breast because of historic trials, such as the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-06, 1 which demonstrated that BCS is safe if combined with radiotherapy. The beneficial effect of radiotherapy was mainly felt to be reduction in rates of locoregional disease only. After BCS, radiotherapy reduces recurrence and breast cancer death, but it may do so more for some groups of women than for others. This paper describes the absolute magnitude of these reductions according to various prognostic and other patient characteristics, and relates the absolute reduction in 15-year risk of breast cancer death to the absolute reduction in 10-year recurrence risk.

Original publication





Book title

50 Landmark Papers: Every Breast Surgeon Should Know

Publication Date



221 - 224